VILAMIT MB- methenamine, phenyl salicylate, sodium phosphate, monobasic, anhydrous, methylene blue anhydrous, and hyoscyamine su

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

METHENAMINE (UNII: J50OIX95QV) (METHENAMINE - UNII:J50OIX95QV), PHENYL SALICYLATE (UNII: 28A37T47QO) (PHENYL SALICYLATE - UNII:28A37T47QO), SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS (UNII: KH7I04HPUU) (PHOSPHATE ION - UNII:NK08V8K8HR), METHYLENE BLUE ANHYDROUS (UNII: 8NAP7826UB) (METHYLENE BLUE CATION - UNII:ZMZ79891ZH), HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X)

Disponible depuis:

Vilvet Pharmaceuticals Inc

DCI (Dénomination commune internationale):

METHENAMINE

Composition:

METHENAMINE 118 mg

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

VILAMIT MB is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. VILAMIT MB is contraindicated in patients with a hypersensitivity to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). A dependence on the use of VILAMIT MB has not been reported and due to the nature of its ingredients, abuse of VILAMIT MB is not expected.

Statut de autorisation:

unapproved drug other

Résumé des caractéristiques du produit

VILAMIT MB- METHENAMINE, PHENYL SALICYLATE, SODIUM PHOSPHATE,
MONOBASIC, ANHYDROUS,
METHYLENE BLUE ANHYDROUS, AND HYOSCYAMINE SULFATE CAPSULE
VILVET PHARMACEUTICALS INC
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
VILAMIT MB CAPSULES
Rx Only
Each Capsule Contains:
METHENAMINE
118 mg
SODIUM PHOSPHATE MONOBASIC
40.8 mg
PHENYL SALICYLATE
36 mg
METHYLENE BLUE
10 mg
HYOSCYAMINE SULFATE
0.12 mg
Inactive Ingredients: Dicalcium Phosphate, Microcrystalline Cellulose,
Sodium Starch Gylcolate,
Magnesium Stearate, Carbopol, FD&C Blue #1, Titanium Dioxide, FD&C
Yellow 5. FD&C Red 3,
Amaranth, and Purified Water.
METHENAMINE. [100-97-0] 1, 3, 5, 7 – Tetraazatricyclo [3.3.1.-1
] decane; hexamethylenetetramine;
HMT; HMTA; hexamine; 1, 3, 5, 7- tetraazaadamantane hexamethylenemine;
Uritone; Urotropin.
C H N ; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine
(hexamethylenetetramine)
exists as colorless, lustrous crystals or white crystalline powder.
Its solutions are alkaline to litmus.
Freely soluble in water, soluble in alcohol and in chloroform.
SODIUM PHOSPHATE MONOBASIC. [7558-80-7] Phosphoric acid sodium salt
(1:1); Sodium
biphosphate; sodium dihydrogen phosphate; acid sodium phosphate;
monosodium orthophosphate;
primary sodium phosphate; H NaO P; mol wt 119.98, H 1.68%, Na 19.16%,
O 53.34%, P 25.82 %.
Monohydrate, white, odorless slightly deliquesce crystals or granules.
At 100 °C loses all its water;
when ignited it converts to metaphosphate. It is freely soluble in
water and practically insoluble in
alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous
solution at 25 °C: 4.5.
PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester;
Salol. C
H O ; mol wt
214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorous
oxy-chloride on a mixture
of phenol and salicylic acid. Phenyl Salicylate exists as white
crystals with a melting point of